Karen M Becker says that modifications to the Food and Drug Administration's pre-market notification process may lead to the introduction of unnecessary regulatory burdens.
The paradigm applied for providing reasonable assurance that every medical device marketed in the US is safe and effective is the most stringent in the world...
Please login to read the full article.
